中國平安AH股均升超1%,獲批設立私募基金已落户深圳前海
保險系證券私募再現新進展,港A兩地保險股齊升。其中,中國平安A股半日收升1.18%報53.91元,H股收升1.43%報46.25港元。消息面上,中國平安近日宣佈,平安集團旗下平安資產管理有限責任公司獲國家金融監督管理總局正式批覆,同意設立恒毅持盈(深圳)私募基金管理有限公司。該公司註冊資本3億元,已落户深圳前海。據瞭解,恒毅持盈將作為基金管理人向平安人壽定向發行契約型私募證券投資基金,首期基金規模300億元。基金將聚焦“長期投資、價值投資”的理念,重點佈局符合政策導向和險資配置需要的優質上市公司,積極發揮保險資金耐心資本的優勢,助力中國資本市場高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.